Patents Examined by Bridget E. Bunner
-
Patent number: 11965176Abstract: A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2) and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).Type: GrantFiled: March 13, 2019Date of Patent: April 23, 2024Assignee: HUNAN SIWEIKANG THERAPEUTICS CO. LTDInventor: Biliang Hu
-
Patent number: 11957714Abstract: The present disclosure relates to non-natural NKG2D receptors attached to mammalian cell surfaces wherein the non-natural receptors do not directly signal or directly activate the cell when the receptor is bound by cognate non-natural ?1-?2 domains of NKG2D ligands modified to specifically bind the non-natural NKG2D receptors. The non-natural ?1-?2 domains of NKG2D ligands may be attached to heterologous atoms or molecules including polypeptides, in some embodiments cytokines or modified cytokines, antibodies or fragments of antibodies.Type: GrantFiled: November 5, 2019Date of Patent: April 16, 2024Assignee: XYPHOS BIOSCIENCES INC.Inventors: Kaman C. Kim, David W. Martin, Jr., Steven Williams
-
Patent number: 11952426Abstract: Methods of treating cancers using a BCMAxCD3 bispecific antibody are described.Type: GrantFiled: May 11, 2021Date of Patent: April 9, 2024Assignee: Janssen Biotech, Inc.Inventors: Homer Adams, Arnob Banerjee, Suzette Girgis, Jenna Goldberg, Tara Stephenson, Raluca Verona, Shun xin Wang lin
-
Patent number: 11944644Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.Type: GrantFiled: December 4, 2018Date of Patent: April 2, 2024Assignees: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, YEDA RESEARCH AND DEVELOPMENT CO. LTDInventors: Zelig Eshhar, Tova Waks, Anat Globerson Levin, Moran Rawet Slobodkin
-
Patent number: 11939387Abstract: The present invention discloses an antibody capable of binding to human interleukin 4 receptor alpha (hIL-4R alpha) and a preparation method and application thereof. The anti-hIL-4R alpha antibody can specifically bind to hIL-4R alpha, has good effects for inhibiting IL-4 and IL-13-induced cell line proliferation and the like, and can be applied to treatment of IL-4R alpha related diseases, such as immune-mediated inflammatory diseases.Type: GrantFiled: October 17, 2022Date of Patent: March 26, 2024Assignee: SHANGHAI MABGEEK BIOTECH. CO., LTDInventors: Chenghai Zhang, Jinlin Guo, Yujing Yuan
-
Patent number: 11939367Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.Type: GrantFiled: March 1, 2021Date of Patent: March 26, 2024Assignees: Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
-
Patent number: 11912776Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 15, 2022Date of Patent: February 27, 2024Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Patent number: 11897963Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Patent number: 11897965Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.Type: GrantFiled: February 16, 2022Date of Patent: February 13, 2024Assignee: AMGEN INC.Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
-
Patent number: 11846629Abstract: The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.Type: GrantFiled: September 20, 2017Date of Patent: December 19, 2023Assignee: Tulane UniversityInventors: Jay Rappaport, Sarah Vakili
-
Patent number: 11833190Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.Type: GrantFiled: January 20, 2021Date of Patent: December 5, 2023Assignee: Janssen Biotech, Inc.Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
-
Patent number: 11802153Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.Type: GrantFiled: October 18, 2018Date of Patent: October 31, 2023Assignee: Forty Seven, Inc.Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
-
Patent number: 11793834Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: GrantFiled: December 11, 2019Date of Patent: October 24, 2023Assignee: Kite Pharma, Inc.Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Patent number: 11780911Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).Type: GrantFiled: May 21, 2020Date of Patent: October 10, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
-
Patent number: 11779630Abstract: Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation.Type: GrantFiled: July 6, 2021Date of Patent: October 10, 2023Assignee: SERPIN PHARMA, LLCInventors: Dana Austin, Cohava Gelber
-
Patent number: 11771741Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.Type: GrantFiled: April 28, 2022Date of Patent: October 3, 2023Assignee: Restore Vision Inc.Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
-
Patent number: 11760792Abstract: The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.Type: GrantFiled: October 15, 2018Date of Patent: September 19, 2023Assignees: NIBEC CO., LTD., CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Yoon Shin Park, Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
-
Patent number: 11761963Abstract: Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor. Also provided are methods for monitoring responsiveness of a patient having cancer to treatment with a CD200 inhibitor, the method comprising: determining expression levels of CD200R1 and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) in a biological sample from the patient, wherein increased expression levels of CD200R1 and the one or more biomarkers, as compared to expression levels in a biological sample of the same type obtained from the subject prior to treatment with the CD200 inhibitor, indicates that the subject is responsive to treatment with the CD200 inhibitor.Type: GrantFiled: September 26, 2018Date of Patent: September 19, 2023Assignee: Alexion Pharmaceuticals, Inc.Inventors: Rui-Ru Ji, Mark Hamilton, Sharon Barr
-
Patent number: 11759518Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.Type: GrantFiled: February 25, 2022Date of Patent: September 19, 2023Assignee: NEC CORPORATIONInventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
-
Patent number: 11739132Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.Type: GrantFiled: February 22, 2022Date of Patent: August 29, 2023Assignee: Werewolf Therapeutics, Inc.Inventors: William Winston, Luke Evnin, Vinay Bhaskar, Giselle Knudsen, Daniel J. Hicklin, Cynthia Seidel-Dugan, Jose Andres Salmeron Garcia, Heather R. Brodkin